HEALTH ADVICE · WEIGHT LOSS
Mounjaro side effects: what to expect and how to manage them
Most Mounjaro side effects are digestive, appear early or after a dose increase, and settle as your body adjusts. Here’s the SmPC-based picture — what’s common, what helps, and the warning signs that need urgent attention.
Why side effects happen
Tirzepatide slows how quickly food leaves your stomach and changes appetite signalling — that’s how it works, and it’s why the most common side effects are stomach-related. The SmPC notes these occur mainly during dose escalation and decrease over time, which is why treatment starts at 2.5 mg and steps up gradually.
Side effects by how common they are
VERY COMMON More than 1 in 10 people
- Nausea, diarrhoea, vomiting, constipation, abdominal pain
- Decreased appetite
- Low blood sugar (hypoglycaemia) when used with a sulphonylurea or insulin
COMMON Up to 1 in 10 people
- Indigestion (dyspepsia), reflux (GORD), bloating, burping, wind
- Dizziness
- Hair loss (reported in about 4.9% on tirzepatide vs 1.0% on placebo; usually mild, most recover while continuing treatment)
- Fatigue
- Injection-site reactions (redness, itching)
- Gallstones (cholelithiasis)
- Low blood pressure–related effects; hypersensitivity reactions
UNCOMMON Up to 1 in 100 people
- Gallbladder inflammation (cholecystitis)
- Acute pancreatitis
- Delayed stomach emptying
STOP AND SEEK HELP Rare but serious
- Severe, persistent stomach pain (may spread to the back), with or without vomiting — possible acute pancreatitis
- Upper-right tummy pain, fever, or yellowing of the skin/eyes — possible gallbladder problems
- Serious allergic reaction (anaphylaxis, angioedema) — swelling of the face, lips or throat, breathing difficulty, fast heartbeat, severe rash. Reported rarely.
- Severe or prolonged vomiting/diarrhoea causing dehydration — can reduce kidney function.
Stop taking Mounjaro and seek medical help immediately. Call 999 if severe or sudden; call 111 (NHS 24 in Scotland) if unsure how urgent it is.
Frequency categories and reactions above are taken from the Mounjaro SmPC (section 4.8), weight-management data. This is not a complete list — see the Patient Information Leaflet.
Practical ways to manage the common ones
Nausea: eat smaller meals slowly, stop when full, and go easy on rich, greasy, or very sweet food in the first weeks. It typically eases within days to a couple of weeks of each dose change.
Constipation: fluids, fibre, and movement; ask us about a suitable laxative if it persists.
Diarrhoea: keep fluids up (see dehydration below) and contact us if severe or lasting more than a few days.
Tiredness or dizziness: often reflects eating much less; make the calories you do eat count, and speak to your prescriber if dizziness persists.
Injection-site reactions: rotate sites weekly; the SmPC reports these are mild in the large majority of cases.
Dehydration: actively watch for this
The SmPC specifically warns that nausea, vomiting and diarrhoea can lead to dehydration, which may cause a decline in kidney function including, rarely, acute kidney failure. Older people may be more susceptible. Drink regularly, more if you’re being sick, and contact your prescriber if you can’t keep fluids down.
Side effects and dose increases
Expect a brief return of mild symptoms after each step up. If side effects at a new dose are more than you’re willing to tolerate, tell your prescriber — staying longer at the lower dose, or stepping back down, are both legitimate options. The goal is the lowest dose that works well for you.
Reporting side effects
Report suspected side effects through the MHRA Yellow Card scheme. Mounjaro carries the black triangle (▼) for additional monitoring — a standard flag for newer medicines meaning reports genuinely add to its safety picture.
Frequently asked questions
The SmPC notes nausea, vomiting and diarrhoea are more frequent during dose escalation and decrease over time — typically days to a few weeks. Persistent or worsening symptoms are a reason to contact your prescriber.
No. Acute pancreatitis is listed as uncommon (up to 1 in 100). But because it is serious, you should stop and seek help immediately for severe, persistent stomach pain.
Hair loss was reported in about 4.9% of people on tirzepatide in weight-management trials, usually mild, with most recovering while continuing treatment.
For mild digestive symptoms, usually not — they tend to pass. For any red-flag symptom above, stop and seek medical help immediately.
Ready to start?
Mounjaro is available through our prescriber-reviewed consultation.
References & sources
- Mounjaro (tirzepatide) Summary of Product Characteristics (SmPC), Eli Lilly and Company Limited — electronic medicines compendium (emc), last updated 16 Apr 2026. medicines.org.uk/emc/product/15481/smpc
- Mounjaro Patient Information Leaflet (PIL) — emc. medicines.org.uk/emc/product/15481/pil
- NICE Technology Appraisal TA1026: Tirzepatide for managing overweight and obesity, published 23 Dec 2024, last updated 01 Sep 2025. nice.org.uk/guidance/ta1026
- MHRA Yellow Card scheme (report suspected side effects). yellowcard.mhra.gov.uk
Content on this page is intended for UK audiences and is for general information only; it does not replace the advice of your prescriber or the Patient Information Leaflet supplied with your medicine.
Medically reviewed by: Tayebah Mahmood, Superintendent Pharmacist (GPhC 2216310).
Content last checked against sources: 3rd July 2026. SmPC last updated on emc 16 Apr 2026; NICE TA1026 last updated 01 Sep 2025.
